



(Please scan this QR code to view the Prospectus)



CORONA REMEDIES LIMITED

Our Company was originally incorporated as 'CORONA Remedies Private Limited', a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to 'CORONA Remedies Limited'. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies ("RoC"), Central Processing Centre, Manesar, Haryana on December 16, 2024. For details in relation to the changes in the Registered Office of our Company, see "*History and Certain Corporate Matters - Changes in the Registered Office of our Company*" on page 253 of the Prospectus dated December 10, 2025 ("*Prospectus*").

Corporate Identity Number: U24231GJ2004PLC044656

Registered and Corporate Office: CORONA House, C – Mondeal Business Park, Near Gurudwara, S. G. Highway, Thaltej, Ahmedabad 380 059, Gujarat, India

Contact Person: Chetna Prabhatkumar Dharajiya, Company Secretary and Compliance Officer; Telephone: +91 79 4023 3000; E-mail: complianceofficer@coronaremedies.com; Website: www.coronaremedies.com

PROMOTERS OF OUR COMPANY: DR. KIRTIKUMAR LAXMIDAS MEHTA, NIRAVKUMAR KIRTIKUMAR MEHTA AND ANKUR KIRTIKUMAR MEHTA

Our Company has filed the Prospectus dated December 10, 2025 with the Registrar of Companies and the Equity Shares (as defined below) are proposed to be listed on the main board platform of the Stock Exchanges and the trading will commence on or about Monday, December 15, 2025.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 6,174,051 EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF CORONA REMEDIES LIMITED ("COMPANY") FOR CASH AT A PRICE OF ₹1,062 PER EQUITY SHARE ("OFFER PRICE") AGGREGATING TO ₹6,553.71 MILLION ("OFFER"), COMPRISING AN OFFER FOR SALE OF 1,223,193 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING TO ₹1,298.41 MILLION BY DR. KIRTIKUMAR LAXMIDAS MEHTA ("PROMOTER SELLING SHAREHOLDER"), 721,691 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING TO ₹766.07 MILLION BY MINAXI KIRTIKUMAR MEHTA, 97,853 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING TO ₹103.87 MILLION BY DIPABAHEN NIRAVKUMAR MEHTA, 97,853 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING TO ₹103.87 MILLION BY BRINDA ANKUR MEHTA ("PROMOTER GROUP SELLING SHAREHOLDERS"), 3,811,613 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING TO ₹4,046.00 MILLION BY SEPIA INVESTMENTS LIMITED, 142,488 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING TO ₹151.25 MILLION BY ANCHOR PARTNERS AND 79,360 EQUITY SHARES OF FACE VALUE OF ₹10 EACH AGGREGATING TO ₹84.24 MILLION BY SAGE INVESTMENT TRUST ("INVESTOR SELLING SHAREHOLDERS", AND ALONG WITH THE PROMOTER SELLING SHAREHOLDER AND PROMOTER GROUP SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS") ("OFFER FOR SALE", AND SUCH EQUITY SHARES OFFERED IN THE OFFER FOR SALE, THE "OFFERED SHARES"). THE OFFER INCLUDED A RESERVATION OF 58,035* EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AGGREGATING TO ₹58.50 MILLION (CONSTITUTING 0.09% OF THE POST OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE 10.09% AND 10.00%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. OUR COMPANY OFFERED A DISCOUNT OF ₹54 ON THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

*A discount of 5.08% on the Offer Price (equivalent of ₹54 per Equity Share) was offered to Eligible Employees bidding in the Employee Reservation Portion.

ANCHOR INVESTOR OFFER PRICE: ₹1,062 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH
OFFER PRICE: ₹1,062 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH
THE OFFER PRICE IS 106.20 TIMES THE FACE VALUE OF THE EQUITY SHARES

RISK TO INVESTORS

For details refer to section titled "Risk Factors" on page 30 of the Prospectus

- 1) **Revenue Dependence on therapeutic areas:** The therapeutic areas of women’s healthcare, cardio-diabeto and pain management contributed to an aggregate of ₹2,257.26 million (or 65.14%) and ₹7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.

2) **Dependence on brands:** Out of the total 71 brands of the Company, 27 “engine” brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our “engine” brands could have an adverse effect on our business, results of operations, financial condition and cash flows.

3) **Revenue concentration in India:** We derive a significant majority of our revenue from our operations within India (constituting 96.34% and 96.33% of our revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for our products in India, or if we fail to successfully expand into international markets, our business, results of operations, financial conditions and cash flows may be adversely affected.

4) **Geographical concentration risk:** A significant portion of our domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of our domestic sales for MAT June 2025). Any adverse developments affecting our sales in these regions could have an adverse effect on our business, results of operations, financial condition and cash flows.

5) **Dependence on therapeutic segments:** 70.10% of our domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and cash flows.

6) **Dependence on suppliers:** We depend on third-party suppliers to procure our raw materials and finished goods, with whom we do not have long term contracts, with our total purchases aggregating to 19.87% and 27.96% of our total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Further, we rely on La Chandra Pharmalab Private Limited, our Associate and Group Company, for the supply of certain active pharmaceutical ingredients in our women’s healthcare therapeutic area. We cannot assure you that we will be in a position to fully control or direct the operations of such supplier to ensure an uninterrupted supply of raw materials and APIs.

7) **Trademark Risk:** As of June 30, 2025, with a portfolio of 71 brands, we held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If we are unable to obtain trademarks for our products and brands or protect other proprietary information, our business, results of operations, financial condition and cash flows may be adversely affected.

8) **Audit and inspections risk:** Our manufacturing units are subject to periodic inspections and audits by regulatory authorities (over 6 in last 3 FYs and the three months ended June 30, 2025) and any inability to obtain the required approvals in a timely manner or at all could have an adverse effect on our business, results of operations, financial condition and cash flow.

9) **Manufacturing facilities risk:** We operate two manufacturing facilities in Bhayla, Ahmedabad, Gujarat and Solan, Himachal Pradesh and two R&D centres (housed within our manufacturing facilities) in India. Any slowdown, breakdown or shutdown in our manufacturing operations may adversely affect our business, results of operations, financial condition and cash flows. Set out below is a breakdown of our revenue from operations attributable to our manufacturing facilities, for the periods and financial years indicated:
- 12) The Selling Shareholders, including our Promoters, will receive the entire proceeds from the Offer for Sale. We will not receive or benefit from any proceeds from the Offer for Sale portion.

13) The Price/Earnings Ratio based on diluted EPS for Financial Year 2025 for the Company at the upper end of the Price band is 43.47 as compared to the average industry peer group P/E ratio of 43.74 as on the date of November 28, 2025.

14) The average cost of acquisition per Equity Share acquired by our Promoter and Selling Shareholders, as on the date of the Prospectus is as follows:

S. No.	Name	Number of Equity Shares of face value of ₹10 each, held	Average cost of acquisition per Equity Share (in ₹)
Promoters			
1.	Dr. Kirtikumar Laxmidas Mehta	13,452,500	0.12
2.	Niravkumar Kirtikumar Mehta	13,458,000	0.29
3.	Ankur Kirtikumar Mehta	13,458,000	0.13
Selling Shareholders			
1.	Sepia Investments Limited	15,896,342	408.76
2.	Anchor Partners	594,341	408.76
3.	Sage Investment Trust	330,847	408.76
4.	Minaxi Kirtikumar Mehta	1,330,258	0.68
5.	Dipabahen Niravkumar Mehta	1,319,900	2.56
6.	Brinda Ankur Mehta	1,319,900	0.25

- 15) Weighted average cost of acquisition of all equity shares transacted in last one year, 18 months and last three years preceding the date of the Prospectus

Period	Weighted average cost of acquisition (in ₹)	Cap Price is 'x' times the weighted average cost of acquisition	Range of acquisition price: lowest price – highest price (in ₹)
Last one year preceding the date of the Prospectus	-	-	-
Last 18 months preceding the date of the Prospectus	0.09	11,800.00	Nil - 0.14
Last three years preceding the date of the Prospectus	0.09	11,800.00	Nil - 0.14

- 16) The details of the Price/Earnings (P/E), Earnings per Share (EPS), Return on Net Worth (RoNW) and Net Asset Value (NAV) per Equity Share for our Company and peer group for the year ended 2025 appear hereunder:

Name of the company	Consolidated	Face value per equity share (₹)	P/E	Revenue from operations (in ₹ million)	EPS (Basic) (₹)	EPS (Diluted) (₹)	RoNW (%)	Net Asset Value per Equity Share (₹)
CORONA Remedies Limited	Consolidated	10.00	43.47*	11,964.15	24.43	24.43	24.65%	99.14
Listed peers								
Abbott India Limited	Standalone	10.00	45.17	64,091.50	665.62	665.62	33.41%	1,992.14
Alkem Laboratories Limited	Consolidated	2.00	31.39	1,29,645.20	181.11	181.11	18.07%	1,002.37
Eris Lifesciences Limited	Consolidated	1.00	61.81	28,936.40	25.85	25.81	12.21%	209.73
GlaxoSmithKline Pharmaceuticals Limited	Consolidated	10.00	46.87	37,492.10	54.76	54.76	47.54%	115.19

Name of the company	Consolidated	Face value per equity share (₹)	P/E	Revenue from operations (in ₹ million)	EPS (Basic) (₹)	EPS (Diluted) (₹)	RoNW (%)	Net Asset Value per Equity Share (₹)
J.B. Chemicals & Pharmaceuticals Limited	Consolidated	1.00	42.60	39,179.89	42.45	41.56	19.21%	220.88
Mankind Pharma Limited	Consolidated	1.00	45.77	1,22,074.40	49.28	49.20	13.89%	352.51
Pfizer Limited	Standalone	10.00	29.63	22,813.50	167.79	167.79	18.20%	921.88
Sanofi India Limited	Standalone	10.00	24.47	20,132.00	179.46	179.46	48.05%	373.68
Torrent Pharmaceuticals Limited	Consolidated	5.00	65.91	1,15,160.90	56.47	56.47	25.18%	224.28

*Basis upper end of Price Band

Source: All the financial information for listed industry peer mentioned above is on a consolidated basis (except Abbott India Limited, Pfizer Limited and Sanofi India Limited which is on a standalone basis) and is sourced from the filings made with stock exchanges available on www.bseindia.com for the Financial Year ending March 31, 2025.

Source for CORONA Remedies Limited: Based on the Restated Consolidated Financial Statements for the year ended March 31, 2025.

- 17) The three BRLMs associated with the Offer have handled 114 public issues in the past three years, out of which 28 issues closed below the offer price on listing date.

Name of BRLMs	Total Issues	Issues Closed Below IPO Price on Listing Date
JM Financial Limited	30	7
IIFL Capital Services Limited (formerly known as IIFL Securities Limited)	26	8
Kotak Mahindra Capital Company Limited	23	4
Common issues handled by the BRLMs	35	9
Total	114	28

Location of manufacturing facility	For the three months ended June 30, 2025		Financial Year					
			2025		2024		2023	
	(₹ in million)	% of revenue from operations	(₹ in million)	% of revenue from operations	(₹ in million)	% of revenue from operations	(₹ in million)	% of revenue from operations
Bhayla, Ahmedabad, Gujarat	1,188.32	34.29%	4,178.88	34.93%	2,736.30	26.97%	1,333.01	15.08%
Solan, Himachal Pradesh	986.22	28.46%	3,479.04	29.08%	3,809.42	37.55%	4,149.90	46.94%
Total revenue from operations from manufacturing facilities	2,174.54	62.75%	7,657.93	64.01%	6,545.72	64.52%	5,482.91	62.02%

- 10) **Development Risk:** R&D costs constituted 1.76% and 1.23% of our total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively do not succeed or the products we commercialize do not perform as expected, this may affect our business and the introduction of new products, and may adversely affect our business, results of operations, financial condition and cash flows.

Particulars	As of June 30, 2025		As of March 31,					
			2025		2024		2023	
	Amount (in ₹ million)	% of total expenses	Amount (in ₹ million)	% of total expenses	Amount (in ₹ million)	% of total expenses	Amount (in ₹ million)	% of total expenses
Research and development expenditure - Revenue	48.69	1.76%	118.10	1.23%	89.96	1.05%	47.63	0.63%

- 11) **Reliance on third party manufacturers:** We rely on third party manufacturers for some of our finished products, which accounted for 37.25% and 35.99% of our total revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Any adverse developments affecting such manufacturers could adversely affect our business, results of operations, financial condition and cash flows.

Particulars	Three months ended June 30, 2025		Financial Year					
			2025		2024		2023	
	(₹ in million)	% of revenue from operations	(₹ in million)	% of revenue from operations	(₹ in million)	% of revenue from operations	(₹ in million)	% of revenue from operations
Third-party manufacturing goods	1,290.89	37.25%	4,306.22	35.99%	3,599.02	35.48%	3,357.59	37.98%

BID/OFFER PROGRAMME:
ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: FRIDAY, DECEMBER 5, 2025
BID/OFFER OPENED ON: MONDAY, DECEMBER 8, 2025
BID/ OFFER CLOSED ON: WEDNESDAY, DECEMBER 10, 2025

The Offer was made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”), read with Regulation 31 of the SEBI ICDR Regulations. The Offer was made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Net Offer was made available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “**QIB Portion**”). Our Company allocated 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“**Anchor Investor Portion**”), of which 40% was made available for allocation as follows, (i) 33.33% was allocated to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids having been received from domestic Mutual Funds, life insurance companies and pension funds at or above the price at which Equity Shares were allocated to Anchor Investors (“**Anchor Investor Allocation Price**”). In the event of under-subscription in (ii) above, the allocation were made to domestic Mutual Funds, subject to valid bids having been received from domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares was added to the remaining QIB Portion (“**Net QIB Portion**”). Further, 5% of the Net QIB Portion was allocated on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion was allocated on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids having been received at or above the Offer Price. However, if the aggregate demand from Mutual Funds was less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion was added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer was allocated to Non-Institutional Investors (“**Non-Institutional Portion**”) out of which (a) one-third of such portion was reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two-third of such portion was reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories will be allocated to applicants in the other sub-category of Non-Institutional Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not less than 35% of the Net Offer was allocated to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids having been received from them at or above the Offer Price (“**Retail portion**”). Further, Equity Shares were allocated on a proportionate basis to Eligible Employees who applied under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) utilised the Application Supported by Blocked Amount (“**ASBA**”) process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid Amount was blocked by the Self Certified Syndicate Banks (“**SCSBs**”) or the Sponsor Bank(s), as applicable, to participate in the Offer. Anchor Investors were not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. See “**Offer Procedure**” beginning on page 415 of the Prospectus.

The bidding for Anchor Investors opened and closed on Friday, December 5, 2025. The company received 17 Anchor Investor Application Forms from 15 Anchor Investors (including 11 domestic mutual funds through 13 Mutual Fund scheme) for 1,834,812 Equity Shares. The Anchor investor price was finalized at ₹ 1,062 per Equity Share. A total of 1,834,804 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 1,948,561,848 of which, 124,312 Equity Shares were allocated to 1 life insurance company.

The Offer received 4,235,535 applications for 6,295,90,640 Equity Shares (prior to rejections) resulting in 101.97 subscription. The details of the applications received in the Offer from various categories are as under: (before rejections):

Sr. No.	Category	No of Applications received*	No. of Equity Shares applied	No. of Equity Shares available for allocation (as per Prospectus)	No. of times Subscribed	Amount (₹)
A	Retail Individual Investors	3,790,863	65,630,950	2,140,606	30.66	69,786,653,426.00
B	Non-Institutional Investors - More than ₹0.20 million Up to ₹1.00 million	253,412	51,795,212	305,801	169.38	54,976,833,912.00
C	Non-Institutional Investors - Above ₹1.00 million	156,437	151,889,192	611,602	248.35	161,305,525,836.00
D	Eligible Employees	34,620	908,096	58,035	15.65	914,061,778.00
E	Qualified Institutional Bidders (excluding Anchors Investors)	186	357,532,378	1,223,203	292.29	379,699,385,436.00
F	Anchor Investors	17	1,834,812	1,834,804	1.00	1,948,570,344.00
	TOTAL	4,235,535	629,590,640	6,174,051	101.97	668,631,030,732.00

**This includes 39,465 applications for 5,52,510 Equity Shares from Retail Individual Investors which were not in bid book but excludes bids (UPI mandates) not accepted by investors.*

Final Demand

A summary of the final demand as at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % to Total
1	1,008	96,208	0.01	96,208	0.01
2	1,009	3,094	0.00	99,302	0.02
3	1,010	14,000	0.00	113,302	0.02
4	1,011	1,974	0.00	115,276	0.02
5	1,012	1,974	0.00	1172,50	0.02
6	1,013	140	0.00	117,390	0.02
7	1,014	490	0.00	117,880	0.02
8	1,015	1,918	0.00	119,798	0.02
9	1,016	98	0.00	119,896	0.02
10	1,017	112	0.00	120,008	0.02
11	1,018	154	0.00	120,162	0.02
12	1,019	196	0.00	120,358	0.02
13	1,020	5,166	0.00	125,524	0.02
14	1,021	434	0.00	125,958	0.02
15	1,022	406	0.00	126,364	0.02
16	1,023	224	0.00	126,588	0.02
17	1,024	434	0.00	127,022	0.02
18	1,025	1,708	0.00	128,730	0.02
19	1,026	1,442	0.00	130,172	0.02
20	1,027	112	0.00	130,284	0.02
21	1,028	42	0.00	130,326	0.02
22	1,029	84	0.00	130,410	0.02
23	1,030	3,780	0.00	134,190	0.02
24	1,031	238	0.00	134,428	0.02
25	1,032	1,036	0.00	135,464	0.02
26	1,033	42	0.00	135,506	0.02
27	1,034	224	0.00	135,730	0.02
28	1,035	588	0.00	136,318	0.02
29	1,036	168	0.00	136,486	0.02
30	1,037	56	0.00	136,542	0.02
31	1,038	14	0.00	136,556	0.02
32	1,039	294	0.00	136,850	0.02
33	1,040	3,640	0.00	140,490	0.02
34	1,041	126	0.00	140,616	0.02
35	1,042	1,022	0.00	141,638	0.02
36	1,043	112	0.00	141,750	0.02
37	1,044	98	0.00	141,848	0.02
38	1,045	1,750	0.00	143,598	0.02
39	1,046	238	0.00	143,836	0.02
40	1,047	56	0.00	143,892	0.02
41	1,048	154	0.00	144,046	0.02
42	1,049	98	0.00	144,144	0.02
43	1,050	11,284	0.00	155,428	0.02
44	1,051	812	0.00	156,240	0.02
45	1,052	15,610	0.00	171,850	0.03
46	1,053	238	0.00	172,088	0.03
47	1,054	364	0.00	172,452	0.03
48	1,055	980	0.00	173,432	0.03
49	1,056	1,078	0.00	174,510	0.03
50	1,057	70	0.00	174,580	0.03
51	1,058	1,022	0.00	175,602	0.03
52	1,059	2,380	0.00	177,982	0.03
53	1,060	27,160	0.00	205,142	0.03
54	1,061	23,506	0.00	228,648	0.04
55	1,062	578,385,220	90.02	578,613,868	90.06
56	CUT OFF	63,871,178	9.94	642,485,046	100.00
	TOTAL			642,485,046	100.00

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on Thursday, December 11, 2025.

A. Allotment to Retail Individual Investors (after rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Investors, who have bid at the Cut-Off Price or at the Offer Price of ₹ 1,062 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 29.29 times (after rejections). The total number of Equity Shares Allotted in Retail Portion is 2,140,606 Equity Shares to 152,900 successful Retail Individual Investors. The category-wise details of the Basis of Allotment are as under (Sample):

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	14	3,307,729	91.68	46,308,206	73.87	1,40,179	42:991	1,962,506
2	28	158,831	4.40	4,447,268	7.09	6,731	42:991	94,234
3	42	49,427	1.37	2,075,934	3.31	2,095	27:637	29,330
4	56	21,523	0.60	1,205,288	1.92	912	5:118	12,768
5	70	18,003	0.50	1,260,210	2.01	763	37:873	10,682
6	84	8,150	0.23	684,600	1.09	344	8:189	4,816
7	98	7,833	0.22	767,634	1.22	332	27:637	4,648
8	112	3,181	0.09	356,272	0.57	135	16:377	1,890
9	126	2,138	0.06	269,388	0.43	91	2:47	1,274
10	140	6,592	0.18	922,880	1.47	279	35:827	3,906
11	154	1,570	0.04	241,780	0.39	67	30:703	938
12	168	1,625	0.04	273,000	0.44	69	20:471	966
13	182	21,307	0.59	3,877,874	6.19	903	42:991	12,642
1 Additional share will be allotted to successful allottees from Sr no. 2 to 13 = 6 shares in ratio of 6:12721							6:12721	
	TOTAL	3,607,909	100.00	62,690,334	100.00	152,900		2,140,606

B. Allotment to Non-Institutional Bidders (more than ₹0.20 million and up to ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹0.20 million Up to ₹1.00 million), who have bid at the Offer Price of ₹ 1,062 per Equity Share, was finalized in consultation with NSE. This category has been subscribed to the extent of 165.48 times (after rejections). The total number of Equity Shares allotted in this category is 305,801 Equity Shares to 1,560 successful applicants. The category-wise details of the Basis of Allotment are as under (Sample):

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	196	234,265	94.61	45,915,940	90.74	1,476	3:476	289,296
2	210	3,815	1.54	801,150	1.58	24	1:159	4,704
3	224	924	0.37	206,976	0.41	6	1:154	1,176
4	238	763	0.31	181,594	0.36	5	5:763	980
5	252	518	0.21	130,536	0.26	3	3:518	588
24	938	436	0.18	408,968	0.81	3	3:436	588
25	434	64	0.03	27,776	0.05	0	0:64	0
26	490	71	0.03	34,790	0.07	0	0:71	0
27	504	47	0.02	23,688	0.05	0	0:47	0
28	518	22	0.01	11,396	0.02	0	0:22	0
53	910	21	0.01	19,110	0.04	0	0:21	0
54	924	33	0.01	30,492	0.06	0	0:33	0
Please Note : 1 (One) lot of 196 shares have been allocated to all the Applicants from Serial No.25 to 53 = 588 shares in ratio of 3:815						3	3:815	588
1 Additional share will be allotted to successful allottees from Sr.no. 2 to 53 = 41 shares in ratio of 41:84							41:84	41
	Total	247,611	100.00	50,603,406	100.00	1,560		305,801

C. Allotment to Non-Institutional Bidders (more than ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹1.00 million), who have bid at the Offer Price of ₹1,062 per Equity Share, was finalized in consultation with NSE. This category has been subscribed to the extent of 246.50 times (after rejections). The total number of Equity Shares allotted in this category is 611,602 Equity Shares to 3,120 successful applicants. The category-wise details of the Basis of Allotment are as under: (Sample)

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	952	149,434	96.25	142,261,168	94.36	3,003	17:846	588,588
2	966	1,387	0.89	1,339,842	0.89	28	13:644	5,488
3	980	1,347	0.87	1,320,060	0.88	27	9:449	5,292
4	994	422	0.27	419,468	0.28	8	4:211	1,568
5	1,008	337	0.22	339,696	0.23	7	7:337	1,372
123	2,842	2	0.00	5,684	0.00	0	0:2	0
124	2,884	1	0.00	2,884	0.00	0	0:1	0
125	2,898	1	0.00	2,898	0.00	0	0:1	0
126	2,912	2	0.00	5,824	0.00	0	0:2	0
127	2,940	6	0.00	17,640	0.01	0	0:6	0
254	139,986	1	0.00	139,986	0.09	0	0:1	0
255	140,000	1	0.00	140,000	0.09	0	0:1	0
Please Note : 1 (One) lot of 196 shares have been allocated to all the Applicants from Serial No.26 to 255 = 2744 shares in ratio of 14:805						14	0:1	2,744
1 Additional share will be allotted to successful allottees from Sr no. 1 to 255 = 82 shares in ratio of 82:3120							14:805	82
	TOTAL	155,270	100.00	150,760,736	100.00	3,120	82:3120	611,602

D. Allotment to Employee Reservation (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Eligible Employee Portion, who have bid at the Offer Price of ₹ 1,062 per Equity Share (Net of employee discount i.e. ₹ 54 per equity share), was finalized in consultation with NSE. This category has been subscribed to the extent of 3.96 times. The total number of Equity Shares allotted in this category is 58,035 Equity Shares to 1,790 successful Eligible employees. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	14	462	20.33	6,468	3.26	136	68:231	1,904
2	28	317	13.95	8,876	4.47	186	186:317	2,604
3	42	203	8.93	8,526	4.30	179	179:203	2,506
4	56	163	7.17	9,128	4.60	163	1:1	2,608
5	70	143	6.29	10,010	5.04	143	1:1	2,860
6	84	82	3.61	6,888	3.47	81	81:82	2,025
7	98	138	6.07	13,524	6.81	137	137:138	3,973
8	112	65	2.86	7,280	3.67	65	1:1	2,145
9	126	33	1.45	4,158	2.09	33	1:1	1,221
10	140	66	2.90	9,240	4.66	66	1:1	2,706
11	154	35	1.54	5,390	2.72	35	1:1	1,575
12	168	20	0.88	3,360	1.69	20	1:1	980
13	182	98	4.31	17,836	8.99	98	1:1	5,194
14	196	249	10.95	48,804	24.59	249	1:1	14,193
15	210	40	1.76	7,840	3.95	40	1:1	2,280
16	224	10	0.44	1,960	0.99	10	1:1	570
17	238	6	0.26	1,176	0.59	6	1:1	342
18	252	14	0.62	2,744	1.38	14	1:1	798
19	266	2	0.09	392	0.20	2	1:1	114
20	280	7	0.31	1,372	0.69	7	1:1	399
21	294	13	0.57	2,548	1.28	13	1:1	741
22	308	6	0.26	1,176	0.59	6	1:1	342
23	322	3	0.13	588	0.30	3	1:1	171
24	336	1	0.04	196	0.10	1	1:1	57
25	350	4	0.18	784	0.39	4	1:1	228
26	378	1	0.04	196	0.10	1	1:1	57
27	392	4	0.18	784	0.39	4	1:1	228
28	406	2	0.09	392	0.20	2	1:1	114
29	420	6	0.26	1,176	0.59	6	1:1	342
30	434	1	0.04	196	0.10	1	1:1	57
31	448	2	0.09	392	0.20	2	1:1	114
32	462	13	0.57	2,548	1.28	13	1:1	741
33	476	2	0.09	392	0.20	2	1:1	114
34	490	62	2.73	12,152	6.12	62	1:1	3,534
1 Additional share will be allotted to successful allottees from Sr no. 15 to 34 = 198 shares in ratio of 198:199							198:199	198
TOTAL		2,273	100.00	198,492	100.00	1,790		58,036